Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing SPN-810 as adjunctive therapy for impulsive aggression in children with ADHD, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Impulsive Aggression

Drugs mentioned

• SPN-810 (viloxazine extended-release)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Impulsive Aggression Comorbid With ADHD | Phase 2 | Status: COMPLETED